Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer – Xconomy
|
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Xconomy The recent stumbles for cancer immunotherapy—specifically, combinations of treatments meant to help boost its effectiveness—continued late Tuesday with some disappointing news from one of the leaders in the field, Bristol-Myers Squibb. Bristol (NYSE: … |
